3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Hepatocellular
19
Neoplasm Metastasis
13
Melanoma
12
Nasopharyngeal Carcinoma
10
Carcinoma, Non-Small-Cell Lung
10
Stomach Neoplasms
8
Rectal Neoplasms
8
Pancreatic Neoplasms
8
Colorectal Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms
6
Locally Advanced Rectal Cancer
6
Carcinoma, Renal Cell
6
Uterine Cervical Neoplasms
4
Recurrence
4
Lymphoma, Extranodal NK-T-Cell
4
Triple Negative Breast Neoplasms
3
Sarcoma
3
Nasopharyngeal Neoplasms
3
Glioblastoma
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Thyroid Neoplasms
2
Solid Tumor
2
Prostatic Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Gastrointestinal Stromal Tumors
2
Interventions
Radiotherapy
6
Doxorubicin
5
Nivolumab
4
pembrolizumab
3
Sunitinib
3
Ifosfamide
3
Gemcitabine
3
Docetaxel
3
pazopanib
2
Radiation Dose Hypofractionation
2
Radiation
2
Methotrexate
2
Ipilimumab
2
Cisplatin
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tremelimumab
1
toripalimab
1
temsirolimus
1
spartalizumab
1
sintilimab
1
ribociclib
1
regorafenib
1
pegfilgrastim
1
liposomal doxorubicin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
itacitinib
1
fludarabine
1
eribulin
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Histiocytoma, Malignant Fibrous
×
spartalizumab
×
Clear all
NCT05961761
2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2
Recruiting
80 enrolled